<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Med Rep</journal-id><journal-id journal-id-type="iso-abbrev">Mol Med Rep</journal-id><journal-title-group><journal-title>Molecular Medicine Reports</journal-title></journal-title-group><issn pub-type="ppub">1791-2997</issn><issn pub-type="epub">1791-3004</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28944878</article-id><article-id pub-id-type="pmc">5865876</article-id><article-id pub-id-type="doi">10.3892/mmr.2017.7532</article-id><article-id pub-id-type="publisher-id">mmr-16-05-7450</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Gene expression analysis: Regulation of key genes associated with mycophenolate mofetil treatment of symptomatic carotid artery stenosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jin</surname><given-names>Feng</given-names></name><xref ref-type="aff" rid="af1-mmr-16-05-7450">1</xref><xref rid="fn1-mmr-16-05-7450" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Kai</given-names></name><xref ref-type="aff" rid="af2-mmr-16-05-7450">2</xref><xref rid="fn1-mmr-16-05-7450" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Xiaochuan</given-names></name><xref ref-type="aff" rid="af3-mmr-16-05-7450">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Zhanpu</given-names></name><xref ref-type="aff" rid="af2-mmr-16-05-7450">2</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Ping</given-names></name><xref ref-type="aff" rid="af1-mmr-16-05-7450">1</xref><xref rid="c1-mmr-16-05-7450" ref-type="corresp"/></contrib></contrib-group><aff id="af1-mmr-16-05-7450"><label>1</label>Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China</aff><aff id="af2-mmr-16-05-7450"><label>2</label>Department of Neurosurgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010050, P.R. China</aff><aff id="af3-mmr-16-05-7450"><label>3</label>Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 630014, P.R. China</aff><author-notes><corresp id="c1-mmr-16-05-7450"><italic>Correspondence to</italic>: Dr Ping Han, Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, Hubei 430022, P.R. China, E-mail: <email>cjr.hanping@vip.163.com</email></corresp><fn id="fn1-mmr-16-05-7450"><label>*</label><p>Contributed equally</p></fn></author-notes><pub-date pub-type="ppub"><month>11</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>20</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>9</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>16</volume><issue>5</issue><fpage>7450</fpage><lpage>7458</lpage><history><date date-type="received"><day>01</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>30</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Jin et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><p>The present study analyzed gene expression arrays to identify differentially-expressed genes (DEGs) between mycophenolate mofetil (MMF)-treated and placebo-treated patients with symptomatic carotid artery stenosis (SCAS). In addition, the key genes involved in the pharmacology of MMF treatment in patients with SCAS were identified. The gene expression dataset was obtained from a Gene Expression Omnibus database, which included 9 MMF-treated and 11 placebo-treated samples. The DEGs were identified between MMF and placebo groups using R software. Furthermore, a protein-protein interaction (PPI) network of the identified DEGS was constructed. The Database for Annotation, Visualization and Integrated Discovery was used to perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of the 19 most significant DEGs. A total of 210 DEGs between the MMF and placebo groups were screened and their PPI was constructed. GO function analysis revealed that the 19 DEGs were predominantly involved in the tyrosine phosphorylation of signal transducer and activator of transcription-5 protein, which is closely associated with the activation of T cells. The KEGG pathway analysis suggested that the main metabolic pathways of the 19 DEGs were associated with the pharmacological functioning of MMF in activated T cells. In conclusion, the present study identified numerous key DEGs associated with SCAS, and the results suggested that v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog and apelin may serve important roles in the MMF treatment of SCAS.</p></abstract><kwd-group><kwd>carotid artery stenosis</kwd><kwd>atherosclerosis</kwd><kwd>genes</kwd><kwd>pathway analysis</kwd><kwd>protein-protein interaction network</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Stroke is the fourth leading cause of mortality and disability in the United States (<xref rid="b1-mmr-16-05-7450" ref-type="bibr">1</xref>), and 10&#x02013;20% of strokes are caused by carotid artery disease (<xref rid="b2-mmr-16-05-7450" ref-type="bibr">2</xref>,<xref rid="b3-mmr-16-05-7450" ref-type="bibr">3</xref>). According to epidemiological data, ~7 million adults in the United States have suffered a stroke (<xref rid="b4-mmr-16-05-7450" ref-type="bibr">4</xref>), of which ischemic strokes account for ~90% (<xref rid="b5-mmr-16-05-7450" ref-type="bibr">5</xref>). In addition, ~10% of ischemic strokes are caused by carotid artery stenosis (CAS) (<xref rid="b6-mmr-16-05-7450" ref-type="bibr">6</xref>). CAS refers to a narrowing or constriction of the lumen of the carotid artery, usually attributed to atherosclerosis (<xref rid="b7-mmr-16-05-7450" ref-type="bibr">7</xref>). The dynamic and complex process of atherosclerosis remains to be fully understood; however, it is well known that atherosclerosis is characterized by the accumulation of lipid particles and fibrous elements, associated with migration and proliferation of smooth muscle cells, in the large arteries (<xref rid="b8-mmr-16-05-7450" ref-type="bibr">8</xref>&#x02013;<xref rid="b10-mmr-16-05-7450" ref-type="bibr">10</xref>).</p><p>Over the past decade, inflammation and the immune response in atherosclerosis have garnered attention. Previous studies have indicated that low-density lipoprotein particles and their content inside the vessel wall are susceptible to oxidation by free radicals, which may initiate the accumulation and invasion of macrophages, eventually lead to a narrowing of the major arteries (<xref rid="b9-mmr-16-05-7450" ref-type="bibr">9</xref>,<xref rid="b11-mmr-16-05-7450" ref-type="bibr">11</xref>).</p><p>During the progression of atherosclerosis, an imbalance between anti-inflammatory and proinflammatory cytokines serves an important role. Previous studies have attempted to identify the immune-associated genes that are involved in atherosclerosis, and achievements have been made (<xref rid="b12-mmr-16-05-7450" ref-type="bibr">12</xref>,<xref rid="b13-mmr-16-05-7450" ref-type="bibr">13</xref>). Superoxide dismutase, which is expressed at higher levels in regions of laminar flow, may combat oxidative stress, and hence limit vascular cell adhesion molecule-1 (VCAM-1) expression and the expression of other inflammatory pathways (<xref rid="b12-mmr-16-05-7450" ref-type="bibr">12</xref>). Nitric oxide arises from endothelial nitric oxide synthase, which is known to be a shear stress-regulated gene, and can inhibit VCAM gene expression through a novel pathway involving inhibition of the activation of nuclear factor-&#x003ba;B, the central transcription factor in vascular inflammation (<xref rid="b13-mmr-16-05-7450" ref-type="bibr">13</xref>). In addition, previous studies have reported that interleukin (IL)-35 may upregulate the expression of anti-inflammatory cytokines (<xref rid="b14-mmr-16-05-7450" ref-type="bibr">14</xref>&#x02013;<xref rid="b16-mmr-16-05-7450" ref-type="bibr">16</xref>). Huang <italic>et al</italic> (<xref rid="b17-mmr-16-05-7450" ref-type="bibr">17</xref>) investigated the effects of IL-35 on atherosclerosis and hypothesized that IL-35 could be considered a novel target for the treatment of atherosclerosis. However, the majority of genes relevant to atherosclerosis remain unknown.</p><p>Mycophenolate mofetil (MMF) is an inhibitor of the enzyme inosine monophosphate dehydroxygenase (IMPDH), and exerts a powerful cytostatic effect on activated T cells by interfering with their DNA synthesis (<xref rid="b18-mmr-16-05-7450" ref-type="bibr">18</xref>). In the present study, gene expression data were obtained from a Gene Expression Omnibus (GEO) dataset uploaded by van Leuven <italic>et al</italic> (<xref rid="b19-mmr-16-05-7450" ref-type="bibr">19</xref>), which included 20 carotid endarterectomy samples from patients with CAS (&#x0003e;70% diameter stenosis on angiography) that were randomly assigned to the following treatment groups: Treatment with 1,000 mg MMF (n=9) or placebo (n=11). Patients were treated with MMF or placebo for &#x02265;2 weeks prior to undergoing carotid endarterectomy (CEA). van Leuven <italic>et al</italic> (<xref rid="b19-mmr-16-05-7450" ref-type="bibr">19</xref>) reported that the inflammatory process in human atherosclerotic plaques could be modified by short-term treatment with MMF, as determined using mRNA expression profiling. However, this previous study did not analyze the expression data in detail, nor did it determine how MMF functioned in the treatment of symptomatic CAS (SCAS) or the molecular mechanisms of SCAS.</p><p>In the present study, the gene expression data were used to identify differentially-expressed genes (DEGs) between MMF-treated and placebo-treated groups, with the aim of identifying potential genes associated with atherosclerosis, which may be considered targets for novel gene therapy. A total of 210 DEGs between the MMF and placebo groups were identified with a threshold of P&#x0003c;0.05. After analyzing the regulatory effects, a regulatory network was constructed based on the DEGs. Subsequently, the data were processed by bioinformatic analyses, including hierarchical clustering, Gene Ontology (GO) terms (molecular function, biological processes and cellular components) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Finally, the 19 most significant DEGs were screened; the results of these analyses indicated that apelin (APLN) and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) may be valuable for characterizing the mechanism underlying immunomodulatory therapy in atherosclerosis.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title/><sec><title>Datasets</title><p>The GSE13922 original mRNA expression profile used in the present study was downloaded from the National Center of Biotechnology Information GEO (<uri xlink:type="simple" xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</uri>). The platform used to analyze these data was the GPL6255 Illumina humanRef-8 v2.0 expression beadchip (Illumina, San Diego, CA, USA).</p></sec><sec><title>Identification of DEGs</title><p>Background correction and quartile data normalization of the downloaded data were performed using the robust multi-array average (RMA) algorithm (<xref rid="b20-mmr-16-05-7450" ref-type="bibr">20</xref>). Probes without a corresponding gene symbol were filtered and the average value of gene symbols with numerous probes was calculated. The expression profile dataset, including 13,985 genes for the 20 samples, was subsequently obtained. Student's t-test was used to identify DEGs between the MMF and placebo groups using the R software LIMMA package (version 3.3.1; <uri xlink:type="simple" xlink:href="http://www.r-project.org">www.r-project.org</uri>) (<xref rid="b21-mmr-16-05-7450" ref-type="bibr">21</xref>). Genes with P&#x0003c;0.05 were considered DEGs and genes with P&#x0003c;0.01 were considered the most significant DEGs between the two treatment groups. The most significant DEGs were screened between the MMF and placebo groups using principal components analysis (PCA). Cluster analysis of the most significant DEGs was applied to generate a heat map, which allowed for visualization of the differential gene expression between the two groups.</p></sec><sec><title>Protein-protein interaction (PPI) network construction and analysis</title><p>The PPI network was constructed from 210 DEGs using the STRING online database (<uri xlink:type="simple" xlink:href="http://www.string-db.org/">http://www.string-db.org/</uri>). PPI pairs with an interaction score &#x0003e;0.4 were used to construct the PPI network. Subsequently, the regulatory relationships between genes were analyzed according to the topological properties of the network. With a threshold of P&#x0003c;0.05 and |logFC|&#x02265;0.5, the key genes in the network were further screened.</p></sec><sec><title>Functional analysis of various DEGs</title><p>In order to identify biological functions associated with the pathogenesis of atherosclerosis, bioinformatics analyses, including hierarchical clustering, GO (<xref rid="b22-mmr-16-05-7450" ref-type="bibr">22</xref>) terms (molecular function, biological processes, cellular components) analysis and KEGG (<xref rid="b23-mmr-16-05-7450" ref-type="bibr">23</xref>) pathway analysis, were conducted for the most significant DEGs, using the online Database for Annotation, Visualization and Integrated Discovery tool (<xref rid="b24-mmr-16-05-7450" ref-type="bibr">24</xref>), based on the method of Expression Analysis Systemic Explorer (EASE) test (<xref rid="b25-mmr-16-05-7450" ref-type="bibr">25</xref>). The enrichment threshold was an EASE score of 0.1.</p></sec></sec></sec><sec sec-type="results"><title>Results</title><sec><title/><sec><title>Data processing</title><p>A total of 13,985 genes in 20 samples were obtained after preprocessing of the expression profile. The original expression datasets were processed into expression estimates using the RMA method. As presented in the box plot in <xref rid="f1-mmr-16-05-7450" ref-type="fig">Fig. 1</xref>, the median of different samples was almost the same following normalization, which indicated a great degree of standardization.</p></sec><sec><title>Identification of DEGs</title><p>The DEGs between the MMF and placebo groups were identified using LIMMA package (<xref rid="b21-mmr-16-05-7450" ref-type="bibr">21</xref>) in R software. A total of 210 DEGs were identified with the threshold of P&#x0003c;0.05, including 19 most significant DEGs with the threshold of P&#x0003c;0.01 (<xref rid="tI-mmr-16-05-7450" ref-type="table">Table I</xref>). Analysis of the most significant DEGs revealed that there were 14 up- and 5 downregulated genes (<xref rid="f2-mmr-16-05-7450" ref-type="fig">Fig. 2</xref>). As presented in <xref rid="f3-mmr-16-05-7450" ref-type="fig">Fig. 3</xref>, all of the selected DEGs were screened using PCA to distinguish between the MMF and placebo groups. In the first principal components, 50.82% of variances were explained, whereas in the second principal component, 9.73% of variances were explained. In total, the resolution degree of variances was 60.55%.</p></sec><sec><title>PPI network construction and analysis</title><p>A total of 189 PPI pairs were obtained from the STRING database. After wiping out the pairs isolated from the major network, the PPI network composed of 172 edges and 105 nodes (<xref rid="f4-mmr-16-05-7450" ref-type="fig">Fig. 4</xref>). In the network, nodes represent genes and edges represent the interaction between genes. The PPI network of DEGs was in a state of high aggregation, which is an essential property of biological networks. With a threshold degree &#x02265;3, a total of 43 genes were selected (<xref rid="tII-mmr-16-05-7450" ref-type="table">Table II</xref>). As shown in <xref rid="f4-mmr-16-05-7450" ref-type="fig">Fig. 4</xref>, tumor protein p53 (degree, 33) and E1A binding protein P300 (degree, 18) had more degrees than the other DEGs.</p></sec><sec><title>GO functional analysis</title><p>Using a threshold of P&#x0003c;0.05, a total of 401 significant GO terms were enriched and the top 10 enriched terms for each category are presented in <xref rid="f5-mmr-16-05-7450" ref-type="fig">Fig. 5</xref>; only 8 terms were enriched in cellular components. The most enriched GO terms of the DEGs were mainly associated with tyrosine phosphorylation of signal transducer and activator of transcription-5 (Stat5) protein, which is closely associated with the activation of T cells.</p></sec><sec><title>KEGG pathway enrichment analysis</title><p>Using a threshold of P&#x0003c;0.05, a total of 6 significant KEGG pathways were enriched (<xref rid="f6-mmr-16-05-7450" ref-type="fig">Fig. 6</xref>). The most enriched KEGG pathways of the DEGs were mainly associated with the pharmacological functioning of MMF in activated T cells, including purine metabolism, glutathione metabolism and pyrimidine metabolism.</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The treatment of CAS includes three modalities: Medical management, carotid artery angioplasty and stenting, and CEA (<xref rid="b26-mmr-16-05-7450" ref-type="bibr">26</xref>). However, there are doubts regarding the efficacy of carotid artery angioplasty and stenting, and CEA, in specific patients (<xref rid="b27-mmr-16-05-7450" ref-type="bibr">27</xref>&#x02013;<xref rid="b29-mmr-16-05-7450" ref-type="bibr">29</xref>). Previous studies have aimed to identify novel treatments and medications for atherosclerosis. Following construction of the hypercholesterolaemic apolipoprotein E-deficient murine model, Chen <italic>et al</italic> (<xref rid="b30-mmr-16-05-7450" ref-type="bibr">30</xref>) demonstrated that preimplantation factor could prevent atherosclerosis via its immunomodulatory effects without affecting serum lipids. In addition, Sun <italic>et al</italic> (<xref rid="b31-mmr-16-05-7450" ref-type="bibr">31</xref>) developed trifunctional Simian virus 40 (SV40)-based nanoparticles for <italic>in vivo</italic> targeting and imaging of atherosclerotic plaques, and targeted SV40 virus-like nanoparticles were revealed to deliver a greater concentration of the anticoagulant drug Hirulog to atherosclerotic plaques.</p><p>It is well known that MMF is a T cell suppressor, which is able to reduce synthesis of guanine via IMPDH inhibition, resulting in the suppression of T cell proliferation (<xref rid="b32-mmr-16-05-7450" ref-type="bibr">32</xref>). van Leuven <italic>et al</italic> (<xref rid="b19-mmr-16-05-7450" ref-type="bibr">19</xref>) demonstrated that treatment with MMF was able to reduce inflammatory cell infiltration, with a concomitant decrease in proinflammatory gene expression in patients with SCAS. The present study downloaded and analyzed a GEO mRNA expression profile uploaded by van Leuven <italic>et al</italic> (<xref rid="b19-mmr-16-05-7450" ref-type="bibr">19</xref>). A total of 210 DEGs were identified between MMF-treated and placebo-treated groups. Subsequently, the 19 most significant DEGs were selected to undergo GO functional analysis and KEGG pathway enrichment analysis. The results revealed that the most enriched KEGG pathway was purine metabolism, indicating that suppression of inflammatory activity served an important role in the MMF treatment of patients with SCAS. Furthermore, with a threshold of degree &#x02265;3 and |logFC|&#x02265;0.5, three genes, APLN, creatine kinase B (CKB) and KIT, were selected as the key genes.</p><p>APLN is a peptide, which was initially identified by Tatemoto <italic>et al</italic> in 1998 (<xref rid="b33-mmr-16-05-7450" ref-type="bibr">33</xref>), that functions as an endogenous ligand for the orphaned G-protein-coupled receptor (APJ) (<xref rid="b34-mmr-16-05-7450" ref-type="bibr">34</xref>). Previous studies have revealed that APJ deficiency can prevent oxidative stress-associated atherosclerosis and that the APLN-APJ system is a mediator of oxidative stress in vascular tissue (<xref rid="b33-mmr-16-05-7450" ref-type="bibr">33</xref>,<xref rid="b35-mmr-16-05-7450" ref-type="bibr">35</xref>&#x02013;<xref rid="b37-mmr-16-05-7450" ref-type="bibr">37</xref>). In the present study, expression of APLN was significantly different between MMF-treated and placebo-treated groups, and APLN was a key gene in the PPI network, indicating that APLN may be a target of MMF for the treatment of SCAS. According to the results of the KEGG analysis, purine metabolism was the most enriched signaling pathway, indicating that MMF modified the atherosclerotic plaque by suppressing activated T cells. Recent studies have also reported that APLN is involved in the immune response (<xref rid="b38-mmr-16-05-7450" ref-type="bibr">38</xref>,<xref rid="b39-mmr-16-05-7450" ref-type="bibr">39</xref>). By analyzing the expression and function of the APLN-APJ system in tumor vasculature, Kidoya <italic>et al</italic> (<xref rid="b38-mmr-16-05-7450" ref-type="bibr">38</xref>) indicated that the APLN-APJ system could induce maturation of tumor vasculature and improve the efficiency of immune therapy. The results of the GO analysis suggested that terms associated with Stat5 were the most enriched, including tyrosine phosphorylation of Stat5 protein, regulation of tyrosine phosphorylation of Stat5 protein and positive regulation of tyrosine phosphorylation of Stat5 protein (<xref rid="tIII-mmr-16-05-7450" ref-type="table">Table III</xref>). Previous studies have indicated that Stat5 has a strong association with T cells. Lindahl <italic>et al</italic> (<xref rid="b40-mmr-16-05-7450" ref-type="bibr">40</xref>) provided evidence to suggest that microRNA-21 is expressed <italic>in situ</italic> in cutaneous T cell lymphomas skin lesions, as induced by IL-2 and IL-15 cytokines, and is regulated by Stat5 in malignant T cells. The APLN-APJ system is also involved in the immune response and Stat3. Han <italic>et al</italic> (<xref rid="b41-mmr-16-05-7450" ref-type="bibr">41</xref>) indicated that binding of phosphorylated-Stat3 to the APLN promoter is the final step underlying proinflammatory cytokine-induced enteric APLN expression during intestinal inflammation. However, whether APLN is involved in the Stat5 signaling remains to be elucidated. It may be hypothesized that APLN affects T cells through the Stat5 signaling pathway; however, further studies are required.</p><p>Mast/stem cell growth factor receptor, also known as proto-oncogene c-Kit, tyrosine-protein kinase Kit, or cluster of differentiation 117 is a receptor tyrosine kinase protein that in humans is encoded by the KIT gene (<xref rid="b42-mmr-16-05-7450" ref-type="bibr">42</xref>). The GO analysis results revealed that KIT was closely associated with tyrosine phosphorylation of Stat5 protein, thus indicating that dysregulation of Stat5 may be important in the process of SCAS.</p><p>Brain-type creatine kinase is a creatine kinase encoded by the CKB gene in humans, which is associated with creatine kinase activity and cellular monovalent inorganic anion homeostasis (<xref rid="b43-mmr-16-05-7450" ref-type="bibr">43</xref>). However, to the best of our knowledge, the involvement of CKB in the process of SCAS has not yet been reported.</p><p>In conclusion, APLN and KIT may serve important roles in the MMF treatment of SCAS. The results of the present study suggested that MMF may upregulate APLN to inhibit the proliferation of T cells through the Stat5 signaling pathway. Further investigation of the function of APLN and KIT in atherosclerosis is urgently required.</p></sec></body><back><ack><title>Acknowledgements</title><p>The present study was supported by the Youth Innovation Fund Projects of Inner Mongolia Medical University (grant no. YKD2013QNCX023), the Health Department Medical Scientific Research Projects of the Inner Mongolia Autonomous Region (grant no. 201302089) and the Health Department Medical Scientific Research Projects of the Inner Mongolia Autonomous Region (grant no. 201302090).</p></ack><ref-list><title>References</title><ref id="b1-mmr-16-05-7450"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>SL</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Kochanek</surname><given-names>KD</given-names></name></person-group><article-title>Deaths: Final data for 2010</article-title><source>National vital statistics reports: From the Centers for Disease Control and Prevention, National Center for Health Statistics, national vital statistics system</source><volume>61</volume><fpage>1</fpage><lpage>117</lpage><year>2013</year><pub-id pub-id-type="pmid">24979972</pub-id></element-citation></ref><ref id="b2-mmr-16-05-7450"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kochanek</surname><given-names>KD</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>SL</given-names></name><name><surname>Minino</surname><given-names>AM</given-names></name><name><surname>Kung</surname><given-names>HC</given-names></name></person-group><article-title>Deaths: Final data for 2009</article-title><source>National vital statistics reports: From the Centers for Disease Control and Prevention, National Center for Health Statistics, national vital statistics system</source><volume>59</volume><fpage>1</fpage><lpage>116</lpage><year>2011</year></element-citation></ref><ref id="b3-mmr-16-05-7450"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grotta</surname><given-names>JC</given-names></name></person-group><article-title>Carotid stenosis</article-title><source>N Engl J Med</source><volume>369</volume><fpage>2360</fpage><lpage>2361</lpage><year>2013</year><pub-id pub-id-type="doi">10.1056/NEJMcp1214999</pub-id><pub-id pub-id-type="pmid">24328480</pub-id></element-citation></ref><ref id="b4-mmr-16-05-7450"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mozaffarian</surname><given-names>D</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Arnett</surname><given-names>DK</given-names></name><name><surname>Blaha</surname><given-names>MJ</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name><name><surname>de Ferranti</surname><given-names>S</given-names></name><name><surname>Despr&#x000e9;s</surname><given-names>JP</given-names></name><name><surname>Fullerton</surname><given-names>HJ</given-names></name><name><surname>Howard</surname><given-names>VJ</given-names></name><etal/></person-group><article-title>Heart disease and stroke statistics-2015 update: a report from the American Heart Association</article-title><source>Circulation</source><volume>131</volume><fpage>e29</fpage><lpage>322</lpage><year>2015</year><pub-id pub-id-type="doi">10.1161/CIR.0000000000000157</pub-id><pub-id pub-id-type="pmid">25520374</pub-id></element-citation></ref><ref id="b5-mmr-16-05-7450"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacco</surname><given-names>RL</given-names></name><name><surname>Adams</surname><given-names>R</given-names></name><name><surname>Albers</surname><given-names>G</given-names></name><name><surname>Alberts</surname><given-names>MJ</given-names></name><name><surname>Benavente</surname><given-names>O</given-names></name><name><surname>Furie</surname><given-names>K</given-names></name><name><surname>Goldstein</surname><given-names>LB</given-names></name><name><surname>Gorelick</surname><given-names>P</given-names></name><name><surname>Halperin</surname><given-names>J</given-names></name><name><surname>Harbaugh</surname><given-names>R</given-names></name><etal/></person-group><article-title>Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline</article-title><source>Circulation</source><volume>37</volume><fpage>e409</fpage><lpage>e449</lpage><year>2006</year></element-citation></ref><ref id="b6-mmr-16-05-7450"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kistler</surname><given-names>JP</given-names></name><name><surname>Furie</surname><given-names>KL</given-names></name></person-group><article-title>Carotid endarterectomy revisited</article-title><source>N Engl J Med</source><volume>342</volume><fpage>1743</fpage><lpage>1745</lpage><year>2000</year><pub-id pub-id-type="doi">10.1056/NEJM200006083422310</pub-id><pub-id pub-id-type="pmid">10841879</pub-id></element-citation></ref><ref id="b7-mmr-16-05-7450"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>MJ</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name></person-group><article-title>Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death</article-title><source>N Engl J Med</source><volume>310</volume><fpage>1137</fpage><lpage>1140</lpage><year>1984</year><pub-id pub-id-type="doi">10.1056/NEJM198405033101801</pub-id><pub-id pub-id-type="pmid">6709008</pub-id></element-citation></ref><ref id="b8-mmr-16-05-7450"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Hou</surname><given-names>P</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name><name><surname>Dong</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Yao</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Geng</surname><given-names>P</given-names></name><etal/></person-group><article-title>The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer</article-title><source>Cell Death Differ</source><volume>24</volume><fpage>59</fpage><lpage>71</lpage><year>2017</year><pub-id pub-id-type="doi">10.1038/cdd.2016.95</pub-id><pub-id pub-id-type="pmid">27716745</pub-id></element-citation></ref><ref id="b9-mmr-16-05-7450"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>Inflammation in atherosclerosis</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>32</volume><fpage>2045</fpage><lpage>2051</lpage><year>2012</year><pub-id pub-id-type="doi">10.1161/ATVBAHA.108.179705</pub-id><!--<pub-id pub-id-type="pmcid">3422754</pub-id>--><pub-id pub-id-type="pmid">22895665</pub-id></element-citation></ref><ref id="b10-mmr-16-05-7450"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocha</surname><given-names>VZ</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>Obesity, inflammation, and atherosclerosis</article-title><source>Nat Rev Cardiol</source><volume>6</volume><fpage>399</fpage><lpage>409</lpage><year>2009</year><pub-id pub-id-type="doi">10.1038/nrcardio.2009.55</pub-id><pub-id pub-id-type="pmid">19399028</pub-id></element-citation></ref><ref id="b11-mmr-16-05-7450"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sparrow</surname><given-names>CP</given-names></name><name><surname>Olszewski</surname><given-names>J</given-names></name></person-group><article-title>Cellular oxidation of low density lipoprotein is caused by thiol production in media containing transition metal ions</article-title><source>J Lipid Res</source><volume>34</volume><fpage>1219</fpage><lpage>1228</lpage><year>1993</year><pub-id pub-id-type="pmid">8103788</pub-id></element-citation></ref><ref id="b12-mmr-16-05-7450"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topper</surname><given-names>JN</given-names></name><name><surname>Gimbrone</surname><given-names>MA</given-names><suffix>Jr</suffix></name></person-group><article-title>Blood flow and vascular gene expression: Fluid shear stress as a modulator of endothelial phenotype</article-title><source>Mol Med Today</source><volume>5</volume><fpage>40</fpage><lpage>46</lpage><year>1999</year><pub-id pub-id-type="doi">10.1016/S1357-4310(98)01372-0</pub-id><pub-id pub-id-type="pmid">10088131</pub-id></element-citation></ref><ref id="b13-mmr-16-05-7450"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Caterina</surname><given-names>R</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Peng</surname><given-names>HB</given-names></name><name><surname>Thannickal</surname><given-names>VJ</given-names></name><name><surname>Rajavashisth</surname><given-names>TB</given-names></name><name><surname>Gimbrone</surname><given-names>MA</given-names><suffix>Jr</suffix></name><name><surname>Shin</surname><given-names>WS</given-names></name><name><surname>Liao</surname><given-names>JK</given-names></name></person-group><article-title>Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines</article-title><source>J Clin Invest</source><volume>96</volume><fpage>60</fpage><lpage>68</lpage><year>1995</year><pub-id pub-id-type="doi">10.1172/JCI118074</pub-id><!--<pub-id pub-id-type="pmcid">185173</pub-id>--><pub-id pub-id-type="pmid">7542286</pub-id></element-citation></ref><ref id="b14-mmr-16-05-7450"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castellani</surname><given-names>ML</given-names></name><name><surname>Anogeianaki</surname><given-names>A</given-names></name><name><surname>Felaco</surname><given-names>P</given-names></name><name><surname>Toniato</surname><given-names>E</given-names></name><name><surname>De Lutiis</surname><given-names>MA</given-names></name><name><surname>Shaik</surname><given-names>B</given-names></name><name><surname>Fulcheri</surname><given-names>M</given-names></name><name><surname>Vecchiet</surname><given-names>J</given-names></name><name><surname>Tet&#x000e8;</surname><given-names>S</given-names></name><name><surname>Salini</surname><given-names>V</given-names></name><etal/></person-group><article-title>IL-35, an anti-inflammatory cytokine which expands CD4+CD25+ Treg Cells</article-title><source>J Biol Regul Homeost Agents</source><volume>24</volume><fpage>131</fpage><lpage>135</lpage><year>2010</year><pub-id pub-id-type="pmid">20487626</pub-id></element-citation></ref><ref id="b15-mmr-16-05-7450"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Or&#x00161;oli&#x00107;</surname><given-names>N</given-names></name></person-group><article-title>Bee venom in cancer therapy</article-title><source>Cancer Metastasis Rev</source><volume>31</volume><fpage>173</fpage><lpage>194</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s10555-011-9339-3</pub-id><pub-id pub-id-type="pmid">22109081</pub-id></element-citation></ref><ref id="b16-mmr-16-05-7450"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Dai</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Ji</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><etal/></person-group><article-title>The expression of a novel anti-inflammatory cytokine IL-35 and its possible significance in childhood asthma</article-title><source>Immunol Lett</source><volume>162</volume><fpage>11</fpage><lpage>17</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.imlet.2014.06.002</pub-id><pub-id pub-id-type="pmid">24970690</pub-id></element-citation></ref><ref id="b17-mmr-16-05-7450"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>YZ</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>QW</given-names></name></person-group><article-title>IL-35: A potential target for the treatment of atherosclerosis</article-title><source>Pharmazie</source><volume>68</volume><fpage>793</fpage><lpage>795</lpage><year>2013</year><pub-id pub-id-type="pmid">24273881</pub-id></element-citation></ref><ref id="b18-mmr-16-05-7450"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname><given-names>AC</given-names></name><name><surname>Eugui</surname><given-names>EM</given-names></name></person-group><article-title>Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection</article-title><source>Transplantation</source><volume>80</volume><issue>2 Suppl</issue><fpage>S181</fpage><lpage>S190</lpage><year>2005</year><pub-id pub-id-type="doi">10.1097/01.tp.0000186390.10150.66</pub-id><pub-id pub-id-type="pmid">16251851</pub-id></element-citation></ref><ref id="b19-mmr-16-05-7450"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Leuven</surname><given-names>SI</given-names></name><name><surname>van Wijk</surname><given-names>DF</given-names></name><name><surname>Volger</surname><given-names>OL</given-names></name><name><surname>de Vries</surname><given-names>JP</given-names></name><name><surname>Van Der Loos</surname><given-names>CM</given-names></name><name><surname>de Kleijn</surname><given-names>DV</given-names></name><name><surname>Horrevoets</surname><given-names>AJ</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><name><surname>Van Der Wal</surname><given-names>AC</given-names></name><name><surname>de Boer</surname><given-names>OJ</given-names></name><etal/></person-group><article-title>Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis</article-title><source>Atherosclerosis</source><volume>211</volume><fpage>231</fpage><lpage>236</lpage><year>2010</year><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2010.01.043</pub-id><pub-id pub-id-type="pmid">20202636</pub-id></element-citation></ref><ref id="b20-mmr-16-05-7450"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Bolstad</surname><given-names>BM</given-names></name><name><surname>Collin</surname><given-names>F</given-names></name><name><surname>Cope</surname><given-names>LM</given-names></name><name><surname>Hobbs</surname><given-names>B</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name></person-group><article-title>Summaries of Affymetrix GeneChip probe level data</article-title><source>Nucleic Acids Res</source><volume>31</volume><fpage>e15</fpage><year>2003</year><pub-id pub-id-type="doi">10.1093/nar/gng015</pub-id><!--<pub-id pub-id-type="pmcid">150247</pub-id>--><pub-id pub-id-type="pmid">12582260</pub-id></element-citation></ref><ref id="b21-mmr-16-05-7450"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diboun</surname><given-names>I</given-names></name><name><surname>Wernisch</surname><given-names>L</given-names></name><name><surname>Orengo</surname><given-names>CA</given-names></name><name><surname>Koltzenburg</surname><given-names>M</given-names></name></person-group><article-title>Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma</article-title><source>BMC Genomics</source><volume>7</volume><fpage>252</fpage><year>2006</year><pub-id pub-id-type="doi">10.1186/1471-2164-7-252</pub-id><!--<pub-id pub-id-type="pmcid">1618401</pub-id>--><pub-id pub-id-type="pmid">17029630</pub-id></element-citation></ref><ref id="b22-mmr-16-05-7450"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashburner</surname><given-names>M</given-names></name><name><surname>Ball</surname><given-names>CA</given-names></name><name><surname>Blake</surname><given-names>JA</given-names></name><name><surname>Botstein</surname><given-names>D</given-names></name><name><surname>Butler</surname><given-names>H</given-names></name><name><surname>Cherry</surname><given-names>JM</given-names></name><name><surname>Davis</surname><given-names>AP</given-names></name><name><surname>Dolinski</surname><given-names>K</given-names></name><name><surname>Dwight</surname><given-names>SS</given-names></name><name><surname>Eppig</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Gene ontology: Tool for the unification of biology. The gene ontology consortium</article-title><source>Nat Genet</source><volume>25</volume><fpage>25</fpage><lpage>29</lpage><year>2000</year><pub-id pub-id-type="doi">10.1038/75556</pub-id><!--<pub-id pub-id-type="pmcid">3037419</pub-id>--><pub-id pub-id-type="pmid">10802651</pub-id></element-citation></ref><ref id="b23-mmr-16-05-7450"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name></person-group><article-title>KEGG: Kyoto encyclopedia of genes and genomes</article-title><source>Nucleic Acids Res</source><volume>28</volume><fpage>27</fpage><lpage>30</lpage><year>2000</year><pub-id pub-id-type="doi">10.1093/nar/28.1.27</pub-id><!--<pub-id pub-id-type="pmcid">102409</pub-id>--><pub-id pub-id-type="pmid">10592173</pub-id></element-citation></ref><ref id="b24-mmr-16-05-7450"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da</surname><given-names>W Huang</given-names></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group><article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title><source>Nat Protoc</source><volume>4</volume><fpage>44</fpage><lpage>57</lpage><year>2009</year><pub-id pub-id-type="pmid">19131956</pub-id></element-citation></ref><ref id="b25-mmr-16-05-7450"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosack</surname><given-names>DA</given-names></name><name><surname>Dennis</surname><given-names>G</given-names><suffix>Jr</suffix></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Lane</surname><given-names>HC</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group><article-title>Identifying biological themes within lists of genes with EASE</article-title><source>Genome Biol</source><volume>4</volume><fpage>R70</fpage><year>2003</year><pub-id pub-id-type="doi">10.1186/gb-2003-4-6-p4</pub-id><!--<pub-id pub-id-type="pmcid">328459</pub-id>--><pub-id pub-id-type="pmid">14519205</pub-id></element-citation></ref><ref id="b26-mmr-16-05-7450"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>C</given-names></name><name><surname>Szuchmacher</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>JB</given-names></name></person-group><article-title>Comparative review of the treatment methodologies of carotid stenosis</article-title><source>Int J Angiol</source><volume>24</volume><fpage>215</fpage><lpage>222</lpage><year>2015</year><pub-id pub-id-type="doi">10.1055/s-0035-1545073</pub-id><!--<pub-id pub-id-type="pmcid">4572011</pub-id>--><pub-id pub-id-type="pmid">26417191</pub-id></element-citation></ref><ref id="b27-mmr-16-05-7450"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukahara</surname><given-names>T</given-names></name><name><surname>Hatano</surname><given-names>T</given-names></name><name><surname>Nakakuki</surname><given-names>T</given-names></name><name><surname>Tsuji</surname><given-names>Y</given-names></name><name><surname>Aoyama</surname><given-names>T</given-names></name><name><surname>Ogata</surname><given-names>H</given-names></name></person-group><article-title>Combined treatment using CEA and CAS for carotid arterial stenosis</article-title><source>Acta Neurochir Suppl</source><volume>103</volume><fpage>109</fpage><lpage>112</lpage><year>2008</year><pub-id pub-id-type="doi">10.1007/978-3-211-76589-0_19</pub-id><pub-id pub-id-type="pmid">18496954</pub-id></element-citation></ref><ref id="b28-mmr-16-05-7450"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Borst</surname><given-names>GJ</given-names></name></person-group><article-title>Recruiting RCTs comparing CAS, CEA and best medical treatment for asymptomatic carotid stenosis</article-title><source>J Cardiovasc Surg (Torino)</source><volume>56</volume><fpage>837</fpage><lpage>844</lpage><year>2015</year><pub-id pub-id-type="pmid">26327611</pub-id></element-citation></ref><ref id="b29-mmr-16-05-7450"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lal</surname><given-names>BK</given-names></name></person-group><article-title>Recurrent carotid stenosis after CEA and CAS: Diagnosis and management</article-title><source>Semin Vasc Surg</source><volume>20</volume><fpage>259</fpage><lpage>266</lpage><year>2007</year><pub-id pub-id-type="doi">10.1053/j.semvascsurg.2007.10.009</pub-id><pub-id pub-id-type="pmid">18082843</pub-id></element-citation></ref><ref id="b30-mmr-16-05-7450"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Rivera</surname><given-names>J</given-names></name><name><surname>Fitzgerald</surname><given-names>M</given-names></name><name><surname>Hausding</surname><given-names>C</given-names></name><name><surname>Ying</surname><given-names>YL</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Todorova</surname><given-names>K</given-names></name><name><surname>Hayrabedyan</surname><given-names>S</given-names></name><name><surname>Barnea</surname><given-names>ER</given-names></name><name><surname>Peter</surname><given-names>K</given-names></name></person-group><article-title>PreImplantation factor prevents atherosclerosis via its immunomodulatory effects without affecting serum lipids</article-title><source>Thromb Haemost</source><volume>115</volume><fpage>1010</fpage><lpage>1024</lpage><year>2016</year><pub-id pub-id-type="doi">10.1160/TH15-08-0640</pub-id><pub-id pub-id-type="pmid">26842698</pub-id></element-citation></ref><ref id="b31-mmr-16-05-7450"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Qi</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>XE</given-names></name><name><surname>Cui</surname><given-names>Z</given-names></name></person-group><article-title>In Vivo targeting and imaging of atherosclerosis using multifunctional virus-like particles of simian virus 40</article-title><source>Nano Lett</source><volume>16</volume><fpage>6164</fpage><lpage>6171</lpage><year>2016</year><pub-id pub-id-type="doi">10.1021/acs.nanolett.6b02386</pub-id><pub-id pub-id-type="pmid">27622963</pub-id></element-citation></ref><ref id="b32-mmr-16-05-7450"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname><given-names>AC</given-names></name><name><surname>Eugui</surname><given-names>EM</given-names></name></person-group><article-title>Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF)</article-title><source>Clin Transplant</source><volume>10</volume><fpage>77</fpage><lpage>84</lpage><year>1996</year><pub-id pub-id-type="pmid">8680053</pub-id></element-citation></ref><ref id="b33-mmr-16-05-7450"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatemoto</surname><given-names>K</given-names></name><name><surname>Hosoya</surname><given-names>M</given-names></name><name><surname>Habata</surname><given-names>Y</given-names></name><name><surname>Fujii</surname><given-names>R</given-names></name><name><surname>Kakegawa</surname><given-names>T</given-names></name><name><surname>Zou</surname><given-names>MX</given-names></name><name><surname>Kawamata</surname><given-names>Y</given-names></name><name><surname>Fukusumi</surname><given-names>S</given-names></name><name><surname>Hinuma</surname><given-names>S</given-names></name><name><surname>Kitada</surname><given-names>C</given-names></name><etal/></person-group><article-title>Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor</article-title><source>Biochem Biophys Res Commun</source><volume>251</volume><fpage>471</fpage><lpage>476</lpage><year>1998</year><pub-id pub-id-type="doi">10.1006/bbrc.1998.9489</pub-id><pub-id pub-id-type="pmid">9792798</pub-id></element-citation></ref><ref id="b34-mmr-16-05-7450"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falc&#x000e3;o-Pires</surname><given-names>I</given-names></name><name><surname>Leite-Moreira</surname><given-names>AF</given-names></name></person-group><article-title>Apelin: A novel neurohumoral modulator of the cardiovascular system. Pathophysiologic importance and potential use as a therapeutic target</article-title><source>Rev Port Cardiol</source><volume>24</volume><fpage>1263</fpage><lpage>1276</lpage><year>2005</year><pub-id pub-id-type="pmid">16398242</pub-id></element-citation></ref><ref id="b35-mmr-16-05-7450"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinz</surname><given-names>MJ</given-names></name><name><surname>Skepper</surname><given-names>JN</given-names></name><name><surname>Davenport</surname><given-names>AP</given-names></name></person-group><article-title>Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells</article-title><source>Regul Pept</source><volume>126</volume><fpage>233</fpage><lpage>240</lpage><year>2005</year><pub-id pub-id-type="doi">10.1016/j.regpep.2004.10.019</pub-id><pub-id pub-id-type="pmid">15664671</pub-id></element-citation></ref><ref id="b36-mmr-16-05-7450"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinz</surname><given-names>MJ</given-names></name><name><surname>Davenport</surname><given-names>AP</given-names></name></person-group><article-title>Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells</article-title><source>Regul Pept</source><volume>118</volume><fpage>119</fpage><lpage>125</lpage><year>2004</year><pub-id pub-id-type="doi">10.1016/j.regpep.2003.11.002</pub-id><pub-id pub-id-type="pmid">15003827</pub-id></element-citation></ref><ref id="b37-mmr-16-05-7450"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>T</given-names></name><name><surname>Kihara</surname><given-names>M</given-names></name><name><surname>Imai</surname><given-names>N</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name><name><surname>Shimoyamada</surname><given-names>H</given-names></name><name><surname>Yasuzaki</surname><given-names>H</given-names></name><name><surname>Ishida</surname><given-names>J</given-names></name><name><surname>Toya</surname><given-names>Y</given-names></name><name><surname>Kiuchi</surname><given-names>Y</given-names></name><name><surname>Hirawa</surname><given-names>N</given-names></name><etal/></person-group><article-title>Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis</article-title><source>Am J Pathol</source><volume>171</volume><fpage>1705</fpage><lpage>1712</lpage><year>2007</year><pub-id pub-id-type="doi">10.2353/ajpath.2007.070471</pub-id><!--<pub-id pub-id-type="pmcid">2043530</pub-id>--><pub-id pub-id-type="pmid">17884970</pub-id></element-citation></ref><ref id="b38-mmr-16-05-7450"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kidoya</surname><given-names>H</given-names></name><name><surname>Kunii</surname><given-names>N</given-names></name><name><surname>Naito</surname><given-names>H</given-names></name><name><surname>Muramatsu</surname><given-names>F</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><name><surname>Nakayama</surname><given-names>T</given-names></name><name><surname>Takakura</surname><given-names>N</given-names></name></person-group><article-title>The apelin/APJ system induces maturation of the tumor vasculature and improves the efficiency of immune therapy</article-title><source>Oncogene</source><volume>31</volume><fpage>3254</fpage><lpage>3264</lpage><year>2012</year><pub-id pub-id-type="doi">10.1038/onc.2011.489</pub-id><pub-id pub-id-type="pmid">22037214</pub-id></element-citation></ref><ref id="b39-mmr-16-05-7450"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>F</given-names></name><name><surname>Khatib</surname><given-names>AM</given-names></name><name><surname>Lopez</surname><given-names>JJ</given-names></name><name><surname>Vatier</surname><given-names>C</given-names></name><name><surname>Turpin</surname><given-names>S</given-names></name><name><surname>Muscat</surname><given-names>A</given-names></name><name><surname>Soulet</surname><given-names>F</given-names></name><name><surname>Aries</surname><given-names>A</given-names></name><name><surname>Jardin</surname><given-names>I</given-names></name><name><surname>Bobe</surname><given-names>R</given-names></name><etal/></person-group><article-title>Apelin: An antithrombotic factor that inhibits platelet function</article-title><source>Blood</source><volume>127</volume><fpage>908</fpage><lpage>920</lpage><year>2016</year><pub-id pub-id-type="doi">10.1182/blood-2014-05-578781</pub-id><pub-id pub-id-type="pmid">26634301</pub-id></element-citation></ref><ref id="b40-mmr-16-05-7450"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindahl</surname><given-names>LM</given-names></name><name><surname>Fredholm</surname><given-names>S</given-names></name><name><surname>Joseph</surname><given-names>C</given-names></name><name><surname>Nielsen</surname><given-names>BS</given-names></name><name><surname>J&#x000f8;nson</surname><given-names>L</given-names></name><name><surname>Willerslev-Olsen</surname><given-names>A</given-names></name><name><surname>Gluud</surname><given-names>M</given-names></name><name><surname>Bl&#x000fc;mel</surname><given-names>E</given-names></name><name><surname>Petersen</surname><given-names>DL</given-names></name><name><surname>Sibbesen</surname><given-names>N</given-names></name><etal/></person-group><article-title>STAT5 induces miR-21 expression in cutaneous T cell lymphoma</article-title><source>Oncotarget</source><volume>7</volume><fpage>45730</fpage><lpage>45744</lpage><year>2016</year><pub-id pub-id-type="doi">10.18632/oncotarget.10160</pub-id><!--<pub-id pub-id-type="pmcid">5216756</pub-id>--><pub-id pub-id-type="pmid">27329723</pub-id></element-citation></ref><ref id="b41-mmr-16-05-7450"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>Englander</surname><given-names>EW</given-names></name><name><surname>Greeley</surname><given-names>GH</given-names><suffix>Jr</suffix></name></person-group><article-title>Involvement of a Stat3 binding site in inflammation-induced enteric apelin expression</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><volume>295</volume><fpage>G1068</fpage><lpage>G1078</lpage><year>2008</year><pub-id pub-id-type="doi">10.1152/ajpgi.90493.2008</pub-id><!--<pub-id pub-id-type="pmcid">2584824</pub-id>--><pub-id pub-id-type="pmid">18818315</pub-id></element-citation></ref><ref id="b42-mmr-16-05-7450"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andre</surname><given-names>C</given-names></name><name><surname>Hampe</surname><given-names>A</given-names></name><name><surname>Lachaume</surname><given-names>P</given-names></name><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>XP</given-names></name><name><surname>Manus</surname><given-names>V</given-names></name><name><surname>Hu</surname><given-names>WX</given-names></name><name><surname>Galibert</surname><given-names>F</given-names></name></person-group><article-title>Sequence analysis of two genomic regions containing the KIT and the FMS receptor tyrosine kinase genes</article-title><source>Genomics</source><volume>39</volume><fpage>216</fpage><lpage>226</lpage><year>1997</year><pub-id pub-id-type="doi">10.1006/geno.1996.4482</pub-id><pub-id pub-id-type="pmid">9027509</pub-id></element-citation></ref><ref id="b43-mmr-16-05-7450"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariman</surname><given-names>EC</given-names></name><name><surname>Schepens</surname><given-names>JT</given-names></name><name><surname>Wieringa</surname><given-names>B</given-names></name></person-group><article-title>Complete nucleotide sequence of the human creatine kinase B gene</article-title><source>Nucleic Acids Res</source><volume>17</volume><fpage>6385</fpage><year>1989</year><pub-id pub-id-type="doi">10.1093/nar/17.15.6385</pub-id><!--<pub-id pub-id-type="pmcid">318286</pub-id>--><pub-id pub-id-type="pmid">2771648</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-mmr-16-05-7450" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Box plot of the mRNA microarray datasets after normalization. The horizontal axis represents the name of the samples, whereas the vertical axis represents the expression value. Short black lines are used to identify the degree of standardization. MMF, mycophenolate mofetil.</p></caption><graphic xlink:href="mmr-16-05-7450-g00"/></fig><fig id="f2-mmr-16-05-7450" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Hierarchical clustering dendrogram of gene expression. A total of 19 DEGs were screened in carotid endarterectomy samples from 11 MMF-treated and 9 placebo-treated patients with symptomatic coronary artery stenosis. A change in color from red to blue indicated high to low expression. DEGs, differentially-expressed genes; MMF, mycophenolate mofetil.</p></caption><graphic xlink:href="mmr-16-05-7450-g01"/></fig><fig id="f3-mmr-16-05-7450" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>PCA of the 19 differentially-expressed genes from 20 samples. The horizontal axis represents the scores of first principal components and the vertical axis represents the scores of second principal components of samples. In the first principal components, 50.82% of variances were explained, whereas in the second principal component, 9.73% of variances were explained. Totally, the resolution degree of variances was 60.55%. PCA, principal components analysis.</p></caption><graphic xlink:href="mmr-16-05-7450-g02"/></fig><fig id="f4-mmr-16-05-7450" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Protein-protein interaction network of DEGs. Red nodes represent upregulated DEGs, and green nodes represent downregulated DEGs; the connecting lines represent the interactions between DEGs. The size of the node is proportional to the degree of the DEG. DEGs, differentially-expressed genes.</p></caption><graphic xlink:href="mmr-16-05-7450-g03"/></fig><fig id="f5-mmr-16-05-7450" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>GO term analysis, separated into biological process, cellular component and molecular function categories, for differentially-expressed genes. Top 10 enriched terms of each category are shown; only 8 terms are presented for cellular components. Red bars represent biological process terms; yellow bars represent cell component terms; blue bars represent molecular function terms. The vertical axis represents the GO category and the horizontal axis represents the -log (p-value). P&#x0003c;0.05 was used as the threshold for selecting significant GO categories. GO, Gene Ontology.</p></caption><graphic xlink:href="mmr-16-05-7450-g04"/></fig><fig id="f6-mmr-16-05-7450" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>KEGG pathway analysis for differentially-expressed genes. The horizontal axis represents the -log (p-value) of the pathway and the vertical axis represents the pathway list. P&#x0003c;0.05 was used as the threshold for selecting the significant KEGG pathways (red bars). KEGG, Kyoto Encyclopedia of Genes and Genomes.</p></caption><graphic xlink:href="mmr-16-05-7450-g05"/></fig><table-wrap id="tI-mmr-16-05-7450" orientation="portrait" position="float"><label>Table I.</label><caption><p>List of the 19 most significant DEGs (P&#x0003c;0.01).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Gene symbol</th><th align="center" valign="bottom" rowspan="1" colspan="1">Gene name</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">logFC</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">AK4</td><td align="left" valign="top" rowspan="1" colspan="1">Adenylate kinase 4</td><td align="center" valign="top" rowspan="1" colspan="1">0.0042</td><td align="center" valign="top" rowspan="1" colspan="1">0.4736</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">APLN</td><td align="left" valign="top" rowspan="1" colspan="1">Apelin</td><td align="center" valign="top" rowspan="1" colspan="1">0.0092</td><td align="center" valign="top" rowspan="1" colspan="1">0.5261</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CKB</td><td align="left" valign="top" rowspan="1" colspan="1">Creatine kinase, brain</td><td align="center" valign="top" rowspan="1" colspan="1">0.0011</td><td align="center" valign="top" rowspan="1" colspan="1">0.9570</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CSF2</td><td align="left" valign="top" rowspan="1" colspan="1">Colony stimulating factor 2 (granulocyte-macrophage)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0097</td><td align="center" valign="top" rowspan="1" colspan="1">0.2979</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EBI3</td><td align="left" valign="top" rowspan="1" colspan="1">Epstein-Barr virus induced 3</td><td align="center" valign="top" rowspan="1" colspan="1">0.0048</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.7416</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ECE1</td><td align="left" valign="top" rowspan="1" colspan="1">Endothelin converting enzyme 1</td><td align="center" valign="top" rowspan="1" colspan="1">0.0088</td><td align="center" valign="top" rowspan="1" colspan="1">0.1873</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FAM102A</td><td align="left" valign="top" rowspan="1" colspan="1">Family with sequence similarity 102, member A</td><td align="center" valign="top" rowspan="1" colspan="1">0.0057</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.2496</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GFRA2</td><td align="left" valign="top" rowspan="1" colspan="1">GDNF family receptor &#x003b1;2</td><td align="center" valign="top" rowspan="1" colspan="1">0.0068</td><td align="center" valign="top" rowspan="1" colspan="1">0.7860</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GPM6B</td><td align="left" valign="top" rowspan="1" colspan="1">Glycoprotein M6B</td><td align="center" valign="top" rowspan="1" colspan="1">0.0064</td><td align="center" valign="top" rowspan="1" colspan="1">0.7289</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HDC</td><td align="left" valign="top" rowspan="1" colspan="1">Histidine decarboxylase</td><td align="center" valign="top" rowspan="1" colspan="1">0.0045</td><td align="center" valign="top" rowspan="1" colspan="1">0.9700</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KIT</td><td align="left" valign="top" rowspan="1" colspan="1">V-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog</td><td align="center" valign="top" rowspan="1" colspan="1">0.0018</td><td align="center" valign="top" rowspan="1" colspan="1">0.6283</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LMO4</td><td align="left" valign="top" rowspan="1" colspan="1">LIM domain only 4</td><td align="center" valign="top" rowspan="1" colspan="1">0.0037</td><td align="center" valign="top" rowspan="1" colspan="1">0.3623</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MGST2</td><td align="left" valign="top" rowspan="1" colspan="1">Microsomal glutathione S-transferase 2</td><td align="center" valign="top" rowspan="1" colspan="1">0.0049</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.3100</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MRPL30</td><td align="left" valign="top" rowspan="1" colspan="1">Mitochondrial ribosomal protein L30</td><td align="center" valign="top" rowspan="1" colspan="1">0.0031</td><td align="center" valign="top" rowspan="1" colspan="1">0.1626</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NSDHL</td><td align="left" valign="top" rowspan="1" colspan="1">NAD(P) dependent steroid dehydrogenase-like</td><td align="center" valign="top" rowspan="1" colspan="1">0.0082</td><td align="center" valign="top" rowspan="1" colspan="1">0.3269</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">POLR2I</td><td align="left" valign="top" rowspan="1" colspan="1">Polymerase (RNA) II (DNA directed) polypeptide I, 14.5kDa</td><td align="center" valign="top" rowspan="1" colspan="1">0.0053</td><td align="center" valign="top" rowspan="1" colspan="1">0.2292</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RRM1</td><td align="left" valign="top" rowspan="1" colspan="1">Ribonucleotide reductase catalytic subunit M1</td><td align="center" valign="top" rowspan="1" colspan="1">0.0094</td><td align="center" valign="top" rowspan="1" colspan="1">0.2653</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SCIN</td><td align="left" valign="top" rowspan="1" colspan="1">Scinderin</td><td align="center" valign="top" rowspan="1" colspan="1">0.0022</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.9358</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WDR41</td><td align="left" valign="top" rowspan="1" colspan="1">WD repeat domain 41</td><td align="center" valign="top" rowspan="1" colspan="1">0.0042</td><td align="center" valign="top" rowspan="1" colspan="1">0.4693</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-mmr-16-05-7450"><p>FC, fold change.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tII-mmr-16-05-7450" orientation="portrait" position="float"><label>Table II.</label><caption><p>DEGs with degree &#x02265;3.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Gene symbol</th><th align="center" valign="bottom" rowspan="1" colspan="1">Gene name</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value</th><th align="center" valign="bottom" rowspan="1" colspan="1">logFC</th><th align="center" valign="bottom" rowspan="1" colspan="1">Degree</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold><underline>CKB</underline></bold></td><td align="left" valign="top" rowspan="1" colspan="1">creatine kinase B</td><td align="center" valign="top" rowspan="1" colspan="1">0.0011</td><td align="center" valign="top" rowspan="1" colspan="1">0.957</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold><underline>KIT</underline></bold></td><td align="left" valign="top" rowspan="1" colspan="1">KIT proto-oncogene receptor tyrosine kinase</td><td align="center" valign="top" rowspan="1" colspan="1">0.0018</td><td align="center" valign="top" rowspan="1" colspan="1">0.6283</td><td align="center" valign="top" rowspan="1" colspan="1">10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold><underline>AK4</underline></bold></td><td align="left" valign="top" rowspan="1" colspan="1">adenylate kinase 4</td><td align="center" valign="top" rowspan="1" colspan="1">0.0042</td><td align="center" valign="top" rowspan="1" colspan="1">0.4736</td><td align="center" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>POLR2I</bold></td><td align="left" valign="top" rowspan="1" colspan="1">RNA polymerase II subunit I</td><td align="center" valign="top" rowspan="1" colspan="1">0.0053</td><td align="center" valign="top" rowspan="1" colspan="1">0.2292</td><td align="center" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold><underline>APLN</underline></bold></td><td align="left" valign="top" rowspan="1" colspan="1">apelin</td><td align="center" valign="top" rowspan="1" colspan="1">0.0092</td><td align="center" valign="top" rowspan="1" colspan="1">0.5261</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>RRM1</bold></td><td align="left" valign="top" rowspan="1" colspan="1">ribonucleotide reductase catalytic subunit M1</td><td align="center" valign="top" rowspan="1" colspan="1">0.0094</td><td align="center" valign="top" rowspan="1" colspan="1">0.2653</td><td align="center" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><bold>CSF2</bold></td><td align="left" valign="top" rowspan="1" colspan="1">colony stimulating factor 2</td><td align="center" valign="top" rowspan="1" colspan="1">0.0097</td><td align="center" valign="top" rowspan="1" colspan="1">0.2979</td><td align="center" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><underline>ENO2</underline></td><td align="left" valign="top" rowspan="1" colspan="1">enolase 2</td><td align="center" valign="top" rowspan="1" colspan="1">0.0143</td><td align="center" valign="top" rowspan="1" colspan="1">0.5576</td><td align="center" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NUP98</td><td align="left" valign="top" rowspan="1" colspan="1">nucleoporin 98</td><td align="center" valign="top" rowspan="1" colspan="1">0.0174</td><td align="center" valign="top" rowspan="1" colspan="1">0.1405</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TLR4</td><td align="left" valign="top" rowspan="1" colspan="1">toll like receptor 4</td><td align="center" valign="top" rowspan="1" colspan="1">0.0179</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.422</td><td align="center" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NES</td><td align="left" valign="top" rowspan="1" colspan="1">nestin</td><td align="center" valign="top" rowspan="1" colspan="1">0.0189</td><td align="center" valign="top" rowspan="1" colspan="1">0.481</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CD2BP2</td><td align="left" valign="top" rowspan="1" colspan="1">CD2 cytoplasmic tail binding protein 2</td><td align="center" valign="top" rowspan="1" colspan="1">0.019</td><td align="center" valign="top" rowspan="1" colspan="1">0.1659</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PPP3CA</td><td align="left" valign="top" rowspan="1" colspan="1">protein phosphatase 3 catalytic subunit &#x003b1;</td><td align="center" valign="top" rowspan="1" colspan="1">0.019</td><td align="center" valign="top" rowspan="1" colspan="1">0.2495</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">COPS6</td><td align="left" valign="top" rowspan="1" colspan="1">COP9 signalosome subunit 6</td><td align="center" valign="top" rowspan="1" colspan="1">0.0196</td><td align="center" valign="top" rowspan="1" colspan="1">0.2328</td><td align="center" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><underline>FST</underline></td><td align="left" valign="top" rowspan="1" colspan="1">follistatin</td><td align="center" valign="top" rowspan="1" colspan="1">0.0199</td><td align="center" valign="top" rowspan="1" colspan="1">0.7444</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EP300</td><td align="left" valign="top" rowspan="1" colspan="1">E1A binding protein p300</td><td align="center" valign="top" rowspan="1" colspan="1">0.0202</td><td align="center" valign="top" rowspan="1" colspan="1">0.2351</td><td align="center" valign="top" rowspan="1" colspan="1">18</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BBS10</td><td align="left" valign="top" rowspan="1" colspan="1">Bardet-Biedl syndrome 10</td><td align="center" valign="top" rowspan="1" colspan="1">0.0211</td><td align="center" valign="top" rowspan="1" colspan="1">0.2222</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MAP1B</td><td align="left" valign="top" rowspan="1" colspan="1">microtubule associated protein 1B</td><td align="center" valign="top" rowspan="1" colspan="1">0.0215</td><td align="center" valign="top" rowspan="1" colspan="1">0.1588</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HNRNPA3</td><td align="left" valign="top" rowspan="1" colspan="1">heterogeneous nuclear ribonucleoprotein A3</td><td align="center" valign="top" rowspan="1" colspan="1">0.022</td><td align="center" valign="top" rowspan="1" colspan="1">0.2015</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PDE4D</td><td align="left" valign="top" rowspan="1" colspan="1">phosphodiesterase 4D</td><td align="center" valign="top" rowspan="1" colspan="1">0.023</td><td align="center" valign="top" rowspan="1" colspan="1">0.2095</td><td align="center" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SOD2</td><td align="left" valign="top" rowspan="1" colspan="1">superoxide dismutase 2, mitochondrial</td><td align="center" valign="top" rowspan="1" colspan="1">0.0236</td><td align="center" valign="top" rowspan="1" colspan="1">0.3115</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PRKDC</td><td align="left" valign="top" rowspan="1" colspan="1">protein kinase, DNA-activated, catalytic polypeptide</td><td align="center" valign="top" rowspan="1" colspan="1">0.0252</td><td align="center" valign="top" rowspan="1" colspan="1">0.3726</td><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TFDP2</td><td align="left" valign="top" rowspan="1" colspan="1">transcription factor Dp-2</td><td align="center" valign="top" rowspan="1" colspan="1">0.026</td><td align="center" valign="top" rowspan="1" colspan="1">0.232</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><underline>GPX1</underline></td><td align="left" valign="top" rowspan="1" colspan="1">glutathione peroxidase 1</td><td align="center" valign="top" rowspan="1" colspan="1">0.0261</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.7343</td><td align="center" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PTGES</td><td align="left" valign="top" rowspan="1" colspan="1">prostaglandin E synthase</td><td align="center" valign="top" rowspan="1" colspan="1">0.0275</td><td align="center" valign="top" rowspan="1" colspan="1">0.2743</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACO1</td><td align="left" valign="top" rowspan="1" colspan="1">aconitase 1</td><td align="center" valign="top" rowspan="1" colspan="1">0.0303</td><td align="center" valign="top" rowspan="1" colspan="1">0.3555</td><td align="center" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RAN</td><td align="left" valign="top" rowspan="1" colspan="1">RAN, member RAS oncogene family</td><td align="center" valign="top" rowspan="1" colspan="1">0.0306</td><td align="center" valign="top" rowspan="1" colspan="1">0.3282</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">COL5A3</td><td align="left" valign="top" rowspan="1" colspan="1">collagen type V &#x003b1;3 chain</td><td align="center" valign="top" rowspan="1" colspan="1">0.0316</td><td align="center" valign="top" rowspan="1" colspan="1">0.1173</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">USF1</td><td align="left" valign="top" rowspan="1" colspan="1">upstream transcription factor 1</td><td align="center" valign="top" rowspan="1" colspan="1">0.0332</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.4322</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SOX9</td><td align="left" valign="top" rowspan="1" colspan="1">SRY-box 9</td><td align="center" valign="top" rowspan="1" colspan="1">0.0345</td><td align="center" valign="top" rowspan="1" colspan="1">0.2414</td><td align="center" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PDE2A</td><td align="left" valign="top" rowspan="1" colspan="1">phosphodiesterase 2A</td><td align="center" valign="top" rowspan="1" colspan="1">0.0356</td><td align="center" valign="top" rowspan="1" colspan="1">0.1566</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CHMP2A</td><td align="left" valign="top" rowspan="1" colspan="1">charged multivesicular body protein 2A</td><td align="center" valign="top" rowspan="1" colspan="1">0.0361</td><td align="center" valign="top" rowspan="1" colspan="1">0.1974</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AK8</td><td align="left" valign="top" rowspan="1" colspan="1">adenylate kinase 8</td><td align="center" valign="top" rowspan="1" colspan="1">0.0362</td><td align="center" valign="top" rowspan="1" colspan="1">0.2411</td><td align="center" valign="top" rowspan="1" colspan="1">8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DHX9</td><td align="left" valign="top" rowspan="1" colspan="1">DEAH-box helicase 9</td><td align="center" valign="top" rowspan="1" colspan="1">0.0367</td><td align="center" valign="top" rowspan="1" colspan="1">0.1559</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><underline>LEP</underline></td><td align="left" valign="top" rowspan="1" colspan="1">leptin</td><td align="center" valign="top" rowspan="1" colspan="1">0.0373</td><td align="center" valign="top" rowspan="1" colspan="1">0.7399</td><td align="center" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TP53</td><td align="left" valign="top" rowspan="1" colspan="1">tumor protein p53</td><td align="center" valign="top" rowspan="1" colspan="1">0.038</td><td align="center" valign="top" rowspan="1" colspan="1">0.1518</td><td align="center" valign="top" rowspan="1" colspan="1">33</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">YWHAE</td><td align="left" valign="top" rowspan="1" colspan="1">tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon</td><td align="center" valign="top" rowspan="1" colspan="1">0.0383</td><td align="center" valign="top" rowspan="1" colspan="1">0.1716</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MCM4</td><td align="left" valign="top" rowspan="1" colspan="1">minichromosome maintenance complex component 4</td><td align="center" valign="top" rowspan="1" colspan="1">0.0393</td><td align="center" valign="top" rowspan="1" colspan="1">0.2495</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PFKP</td><td align="left" valign="top" rowspan="1" colspan="1">phosphofructokinase, platelet</td><td align="center" valign="top" rowspan="1" colspan="1">0.0395</td><td align="center" valign="top" rowspan="1" colspan="1">0.3782</td><td align="center" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LMNA</td><td align="left" valign="top" rowspan="1" colspan="1">lamin A/C</td><td align="center" valign="top" rowspan="1" colspan="1">0.0446</td><td align="center" valign="top" rowspan="1" colspan="1">0.4168</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CCT3</td><td align="left" valign="top" rowspan="1" colspan="1">chaperonin containing TCP1 subunit 3</td><td align="center" valign="top" rowspan="1" colspan="1">0.0446</td><td align="center" valign="top" rowspan="1" colspan="1">0.2518</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMP2</td><td align="left" valign="top" rowspan="1" colspan="1">bone morphogenetic protein 2</td><td align="center" valign="top" rowspan="1" colspan="1">0.0458</td><td align="center" valign="top" rowspan="1" colspan="1">0.1583</td><td align="center" valign="top" rowspan="1" colspan="1">11</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DYRK1A</td><td align="left" valign="top" rowspan="1" colspan="1">dual specificity tyrosine phosphorylation regulated kinase 1A</td><td align="center" valign="top" rowspan="1" colspan="1">0.0495</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.2047</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-mmr-16-05-7450"><p>FC, fold change. Gene symbols shown in bold represent genes with P&#x0003c;0.01 and underlined genes represent the gene with |log fold change|&#x02265;0.5.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIII-mmr-16-05-7450" orientation="portrait" position="float"><label>Table III.</label><caption><p>Most significantly enriched GO terms (P&#x0003c;0.001).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">GO ID</th><th align="left" valign="bottom" rowspan="1" colspan="1">GO term</th><th align="center" valign="bottom" rowspan="1" colspan="1">Associated genes</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">GO:0048513</td><td align="left" valign="top" rowspan="1" colspan="1">Organ development</td><td align="left" valign="top" rowspan="1" colspan="1">AK4, APLN, CKB, CSF2, ECE1, GPM6B, KIT, LMO4, NSDHL, SCIN</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GO:0048731</td><td align="left" valign="top" rowspan="1" colspan="1">System development</td><td align="left" valign="top" rowspan="1" colspan="1">AK4, APLN, CKB, CSF2, ECE1, GFRA2, GPM6B, KIT, LMO4, NSDHL, SCIN</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GO:0042523</td><td align="left" valign="top" rowspan="1" colspan="1">Positive regulation of tyrosine phosphorylation of Stat5 protein</td><td align="left" valign="top" rowspan="1" colspan="1">CSF2, KIT</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GO:0042522</td><td align="left" valign="top" rowspan="1" colspan="1">Regulation of tyrosine phosphorylation of Stat5 protein</td><td align="left" valign="top" rowspan="1" colspan="1">CSF2, KIT</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GO:0042506</td><td align="left" valign="top" rowspan="1" colspan="1">Tyrosine phosphorylation of Stat5 protein</td><td align="left" valign="top" rowspan="1" colspan="1">CSF2, KIT</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GO:0030219</td><td align="left" valign="top" rowspan="1" colspan="1">Megakaryocyte differentiation</td><td align="left" valign="top" rowspan="1" colspan="1">KIT, SCIN</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GO:0048856</td><td align="left" valign="top" rowspan="1" colspan="1">Anatomical structure development</td><td align="left" valign="top" rowspan="1" colspan="1">AK4, APLN, CKB, CSF2, ECE1, GFRA2, GPM6B, KIT, LMO4, NSDHL, SCIN</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GO:0007275</td><td align="left" valign="top" rowspan="1" colspan="1">Multicellular organismal development</td><td align="left" valign="top" rowspan="1" colspan="1">AK4, APLN, CKB, CSF2, ECE1, GFRA2, GPM6B, KIT, LMO4, NSDHL, SCIN</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GO:0044087</td><td align="left" valign="top" rowspan="1" colspan="1">Regulation of cellular component biogenesis</td><td align="left" valign="top" rowspan="1" colspan="1">CSF2, GPM6B, LMO4, SCIN</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GO:0034311</td><td align="left" valign="top" rowspan="1" colspan="1">Diol metabolic process</td><td align="left" valign="top" rowspan="1" colspan="1">AK4, HDC</td></tr></tbody></table></table-wrap></floats-group></article>